We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Munch-a-Biotech Today

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (3121)1/31/2018 11:28:51 PM
From: Miljenko Zuanic   of 3158
It is for the open market, as well for negotiated private transactions, that is related to 10b5-1.

For years VRTX sucked money out of SH, increasing shares count (also by dilution from options/awards). Cumulative they still did not capture capital investment,... they are still negative,....they still have $5B in accumulated deficit, so current EXCESS cash is (in majority) from STOCK offering AND OTHER DILUTIVE FINANCING, not EARNING FROM BUSINESS.

Everyone need bit of luck in this business, when they have nothing left they turned toward CF...and they have game changing candidates. Great, for years management and boards have financial benefits, now SH can benefit from appreciated SP. But, if the want to award anyone, cash should be distributed to SH as one time dividend or something similar. And, if BofD want to thanks SH for long standing support by controlling and reducing dilution, ...well they can ask management to rip 1.2M shares from their options awards.

PS: This is not related only to VRTX, to many bios, old and new.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext